World tour: Xelum R&D stops off in Nuremberg

Bosch Packaging Technology’s Xelum R&D for the continuous production of oral solid dosage (OSD) forms holds substantial potential: since it was first introduced to selected customers in 2018, the compact, innovative machine has attracted considerable interest. Now Bosch is taking the Xelum production platform’s ‘little sister’ on a world tour.

The first stops on the tour are at the Interphex in New York from April 2 to 4, followed by Europe, more precisely Nuremberg. At the Powtech from April 9 to 11, the Xelum R&D will first be unveiled to the German public. “The Powtech is a very important show for us, where we traditionally meet and talk with a large number of customers,” says Fritz-Martin Scholz, product manager Xelum at Bosch Packaging Technology. “Moreover, there is a strong focus on efficiency and speed in production and development – challenges that Xelum can help overcome.”


A shorter path from the lab to production

The Xelum R&D significantly shortens the path from the lab to production. But what’s its secret?
The new laboratory unit uses the same components and process parameters as the Xelum production platform from Bosch. This paves the way for a direct 1-to-1 transfer and does away with the need for a scale-up, which also means pharmaceutical manufacturers can accelerate development and reduce time-to-market. In addition, DoE (Design of Experiment) software support and automation round out the system’s user-friendly handling.
In contrast to the commonly used mass flow rate, excipients and active ingredients are precisely dosed as a discrete mass in the Xelum R&D. The system doses, mixes and granulates individual packages (‘X-keys’), which continuously run through the process chain and are successively removed from the machine.
In this regard, Bosch relies on fluid bed processors developed by its subsidiary Hüttlin. Since granulating and drying take place in the same process unit, there’s no need to transfer wet granules – which also means that production quantities ranging from less than 250 grams to ten kilograms can be processed per hour using an automated cycle. Production with highly potent active ingredients is an available option.

The Xelum R&D tour stops at a glance:

  • Interphex in New York (April 2-4)
  • Powtech in Nuremberg (April 9-11)
  • Interphex Japan in Tokyo (July 3-5)
  • CPhI / P-Mec worldwide in Frankfurt (November 5-7)
  • Pharmtech in Moscow (November 19-22)


Nicole König
Marketing Manager
Phone: +49 7951 402-648

Top of page